# US 2025/0144066 A1 · Prevention and Treatment of Parasitic Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144066 A1
- Document ID: US20250144066A1
- Status: Published application
- Kind: A1
- Application number: 19/014,539
- Filed: 2025-01-09
- Published: 2025-05-08
- Earliest claimed: 2017-05-31
- Inventors: Steven BARANOWITZ
- Web page: https://patentgrep.com/patent/US20250144066A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61P 31/14: for RNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides for treatment of parasitic infections. It does this using agents and methods with little toxicity compared to existing therapies.

## Claims

### Claim 1

A method of treating a parasitic infection in a patient, the method comprising the steps of:
selecting a patient in need of treating a parasitic infection; and
administering to the patient at least one agent which depletes guanosine-containing nucleosides and nucleotides,
wherein the parasitic infection is treated in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the parasitic infection is selected from the group consisting of roundworms, flatworms, protozoa, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the parasitic infection is selected from the group consisting of Entamoeba histolytica; Giardia lamblia; Trichomonas vaginalis; Plasmodium falciparum; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax; Trypanosoma cruzi; Ascaris lumbricoides; Trichinella spiralis; Toxoplasma gondii; Leishmania donovani; Leishmania tropica; Leishmania braziliensis; Schistosoma mansoni; Schistosoma japonicum; Schistosoma haematobium; Cyclospora cayetanesis; Crytosporidium, Cystoisospora species; Naegleria fowleri; Acanthamoeba species; Sappinia diploidea; Sappinia pedata; Balamuthia mandrillaris; Pneumocystis jiroveci Plasmodium knowlesi; Babesia microti; Babesia divergens; Babesia duncani; Babesia; Trypanosoma brucei rhodesiense; Trypanosoma brucei gambiense; Balantidium coli; Dientamoeba fragilis; Phylum: Microsporidia; Sarcocystis; Baylisascaris; Necator americanus; Ancylostoma duodenale; Strongloides stercoralis; Trichinella pseudospiralis; Trichinella nelsoni; Trichinella britovi; Trichinella nativa; Trichuris trichiura; Enterobius vermicularis; Anisakis simplex; Pseudoterranova decipiens; Trichostrongylus, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one agent which depletes guanosine-containing nucleosides and nucleotides is selected from the group consisting of mycophenolate, IMPDH enzyme inhibitors, agents which bind to guanine, or guanosine-containing nucleosides and nucleotides, and combinations thereof.

### Claim 5

A method of treating a parasitic infection in a patient, the method comprising the steps of:
selecting a patient in need of treating a parasitic infection; and
administering to the patient at least one agent selected from the group consisting of minocycline, doxycycline, tetracycline, tetracycline derivatives, and combinations thereof,
wherein the parasitic infection is treated in the patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein the parasitic infection is selected from the group consisting of roundworms, flatworms, protozoa, and combinations thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein the parasitic infection is selected from the group consisting of Entamoeba histolytica; Giardia lamblia; Trichomonas vaginalis; Plasmodium falciparum; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax; Trypanosoma cruzi; Ascaris lumbricoides; Trichinella spiralis; Toxoplasma gondii; Leishmania donovani; Leishmania tropica; Leishmania braziliensis; Schistosoma mansoni; Schistosoma japonicum; Schistosoma haematobium; Cyclospora cayetanesis; Crytosporidium, Cystoisospora species; Naegleria fowleri; Acanthamoeba species; Sappinia diploidea; Sappinia pedata; Balamuthia mandrillaris; Pneumocystis jiroveci Plasmodium knowlesi; Babesia microti; Babesia divergens; Babesia duncani; Babesia; Trypanosoma brucei rhodesiense; Trypanosoma brucei gambiense; Balantidium coli; Dientamoeba fragilis; Phylum: Microsporidia; Sarcocystis; Baylisascaris; Necator americanus; Ancylostoma duodenale; Strongloides stercoralis; Trichinella pseudospiralis; Trichinella nelsoni; Trichinella britovi; Trichinella nativa; Trichuris trichiura; Enterobius vermicularis; Anisakis simplex; Pseudoterranova decipiens; Trichostrongylus, and combinations thereof.

### Claim 8

A method of preventing and/or treating a parasitic infection in a patient, the method comprising the steps of:
selecting a patient in need of preventing and/or treating a viral infection; and
administering to the patient at least one first agent which depletes guanosine-containing nucleosides and nucleotides and at least one additional agent selected from the group consisting of minocycline, doxycycline, tetracycline, tetracycline derivatives, and combinations thereof,
wherein the parasitic infection is prevented and/or treated in the patient.

### Claim 9 (depends on 8)

The method of claim 8, wherein the parasitic infection is selected from the group consisting of roundworms, flatworms, protozoa, and combinations thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein the parasitic infection is selected from the group consisting of Entamoeba histolytica; Giardia lamblia; Trichomonas vaginalis; Plasmodium falciparum; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax; Trypanosoma cruzi; Ascaris lumbricoides; Trichinella spiralis; Toxoplasma gondii; Leishmania donovani; Leishmania tropica; Leishmania braziliensis; Schistosoma mansoni; Schistosoma japonicum; Schistosoma haematobium; Cyclospora cayetanesis; Crytosporidium, Cystoisospora species; Naegleria fowleri; Acanthamoeba species; Sappinia diploidea; Sappinia pedata; Balamuthia mandrillaris; Pneumocystis jiroveci Plasmodium knowlesi; Babesia microti; Babesia divergens; Babesia duncani; Babesia; Trypanosoma brucei rhodesiense; Trypanosoma brucei gambiense; Balantidium coli; Dientamoeba fragilis; Phylum: Microsporidia; Sarcocystis; Baylisascaris; Necator americanus; Ancylostoma duodenale; Strongloides stercoralis; Trichinella pseudospiralis; Trichinella nelsoni; Trichinella britovi; Trichinella nativa; Trichuris trichiura; Enterobius vermicularis; Anisakis simplex; Pseudoterranova decipiens; Trichostrongylus, and combinations thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein the at least one first agent which depletes guanosine-containing nucleosides and nucleotides is selected from the group consisting of mycophenolate, IMPDH enzyme inhibitors, agents which bind to guanine, or guanosine-containing nucleosides and nucleotides, and combinations thereof.

### Claim 12

A pharmaceutical composition comprising:
(i) at least one first agent which depletes guanosine-containing nucleosides and nucleotides; and
(ii) at least one second agent selected from the group consisting of minocycline, doxycycline, tetracycline, tetracycline derivatives, L-DOPA, dopamine, and combinations thereof; wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the at least one agent which depletes guanosine-containing nucleosides and nucleotides is selected from the group consisting of mycophenolate, IMPDH enzyme inhibitors, agents which bind to guanine, or guanosine-containing nucleosides and nucleotides, and combinations thereof.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is formulated or manufactured as a liquid, an elixir, an aerosol, a spray, a powder, a tablet, a pill, a capsule, a gel, a geltab, a nanosuspension, a nanoparticle, an extended release dosage form, or a topical formulation.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the at least one first agent and at least one second agent are in the same dosage form.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the at least one first agent and at least one second agent are in separate dosage forms.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is formulated or manufactured as a liquid, an elixir, an aerosol, a spray, a powder, a tablet, a pill, a capsule, a gel, a geltab, a nanosuspension, a nanoparticle, an extended release dosage form, or a topical formulation.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is in a form for topical administration.
